menu
    • menu
    [{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Nephrology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase III","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Telotristat Etiprate","moa":"Tryptophan 5-hydroxylase","graph1":"Immunology","graph2":"Phase II","graph3":"Lexicon pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lexicon pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lexicon pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Telotristat Etiprate

    Menu

    Telotristat Etiprate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ipsen

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Ipsen

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With N...

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2018

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ipsen

                            France arrow
                            BOS Manchester
                            Not Confirmed

                            Ipsen

                            France arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Ins...

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2016

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in...

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 21, 2014

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Open-Label Food Effect Study of Telotristat Etiprate

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2014

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Thorough QT Study of Telotristat Etiprate

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 04, 2014

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2014

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Telotristat Etiprate for Carcinoid Syndrome Therapy

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoid Tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 14, 2014

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoid Tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 01, 2014

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoid Tumor.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 03, 2012

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to M...

                            Details : Telotristat Etiprate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2011

                            Lead Product(s) : Telotristat Etiprate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth